Business Context and Reporting Period
MiMedx Group, Inc. filed this Form 8-K on March 30, 2018, to disclose a material definitive agreement. The filing relates to a Third Amendment to the Company's Credit Agreement dated October 12, 2015, with Bank of America, N.A. as administrative agent.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. However, it notes that the Company has not drawn on the Credit Agreement since its inception in October 2015. Management stated that cash from operating activities and existing cash equivalents are expected to meet operational liquidity needs and fund planned investing activities for the next twelve months.
Material Changes and Agreements
- Successor Reference Rate: The amendment establishes a mechanism to determine a successor reference rate to LIBOR if it becomes unavailable or is replaced as a market benchmark.
- Filing Conditions: Borrowing or letter of credit issuance is now conditioned on the filing of the Company's 2017 Annual Report (Form 10-K) and required quarterly reports (Form 10-Q).
- Deadline Extension: The deadline for filing the specified 2017 reports has been extended to August 28, 2018.
Outlook, Risks, and Contingencies
The Company highlighted a significant contingency regarding its financial reporting. As noted in a February 20, 2018 press release, the Company cannot release audited financial results or file its 2017 Form 10-K until its Audit Committee completes an ongoing investigation. Management cautioned that the extension granted by lenders for filing reports should not be interpreted as an indication of when the investigation will conclude. The filing includes standard forward-looking statement disclaimers regarding risks and uncertainties.
Investor Verification Checklist
- Verify the status and expected completion date of the Audit Committee's investigation.
- Confirm the timeline for the filing of the delayed 2017 Form 10-K and associated 10-Q reports.
- Review the full text of the Third Amendment (Exhibit 10.1) for specific terms regarding the LIBOR successor rate mechanism.
- Monitor future filings for any updates on the Company's liquidity position or ability to meet operational needs without drawing on the credit facility.